What is the 13F Pro Quality Score for CPRX?

13F Pro ranks CATALYST PHARMACEUTICALS, INC. (CPRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CPRX's current score at https://13fpro.ai/company/CPRX (free sign-up required for the full ranking).

Which hedge funds own the most CPRX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CPRX include BlackRock,, STATE STREET, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/CPRX as soon as new 13F filings post.

Where does 13F Pro source CPRX data?

All CATALYST PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. CATALYST PHARMACEUTICALS, INC. files with the SEC under CIK 1369568. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CPRX in?

CATALYST PHARMACEUTICALS, INC. (CPRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives CPRX's revenue?

Per CATALYST PHARMACEUTICALS, INC.'s latest 10-Q filed with the SEC on 2026-05-11, the biggest revenue drivers are: Product revenue, net ($149.3M, +5.6% YoY); FIRDAPSE® ($98.9M, +18.1% YoY); AGAMREE® ($36.7M, +66.6% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/CPRX.

What are CPRX's largest expenses?

CATALYST PHARMACEUTICALS, INC.'s latest 10-Q reports these as the largest expense items: Selling, general and administrative ($49.3M, +5.1% YoY); Cost of sales ($14.5M, -19% YoY); Amortization of intangible assets ($9.7M). Sourced directly from SEC EDGAR filing text for Q1 FY2026 (quarter ended March 31, 2026).

How often is CPRX research updated on 13F Pro?

CPRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CATALYST PHARMACEUTICALS, INC.(CPRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1369568 CPRX stock profile & AI dashboard →

13F Pro Quality Score

74.0/100

Rank #123 of 2,961 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

80.3/100

Profitability

93.7/100

Balance Sheet

96.6/100

Earnings Quality

60.6/100

Free Cash Flow

87.8/100

Institutional Flow

59.4/100

Revenue Scale

40.1/100

Dilution Risk

27.3/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CPRX Scores 74/100

exact factor attribution · 2026-08-29

CPRX's composite is driven by revenue growth and profitability, held back by shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+7.1 pts

86th pct

Profitability

+5.8 pts

89th pct

Free cash flow

+5.0 pts

83th pct

Capital efficiency

+4.6 pts

96th pct

Earnings growth

+2.2 pts

93th pct

Earnings quality

+1.0 pts

60th pct

Institutional flow

+0.3 pts

56th pct

Scale

-1.0 pts

43th pct

Shareholder dilution

-1.1 pts

27th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

CPRX Stock Analysis & AI Quality Score

Data updated 2026-08-29

AI stock analysis and institutional research for CATALYST PHARMACEUTICALS, INC. (CPRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CPRX at 74.0/100 on a 32-signal composite quality model, placing it at rank #123 of 2,961 stocks — the top 5% of the AI-ranked universe. CPRX scores in the top quartile across balance sheet strength (96.6), profitability (93.7), free cash flow (87.8). Shareholder dilution risk is elevated at 27.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), CATALYST PHARMACEUTICALS, INC. reports quarterly revenue of $149.4M, net income of $63.7M, an operating margin of 49.0%. Top institutional holders of CPRX by reported 13-F value include BlackRock, STATE STREET, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CPRX trades on the Nasdaq exchange and files with the SEC under CIK 1369568. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CPRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CATALYST PHARMACEUTICALS, INC. directly from SEC EDGAR. CATALYST PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 72 and 83 since 2021, currently 74.0 — a stable long-term trajectory across 67 quarterly and live scoring snapshots.

✦

Fun facts about CATALYST PHARMACEUTICALS, INC.

Quirks, history, and lore behind CPRX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · small-cap · listed on Nasdaq · headquartered in Florida.
2
The Numbers
Annual revenue in the range of $200–300 million — modest by pharma standards, but built almost entirely on a single rare-disease franchise with strong pricing power.
3
The History
Founded in the early 2000s, the company spent years developing drugs for rare neuromuscular conditions before finally landing an FDA-approved blockbuster that put it on the map.
4
The Secret
Its core drug targets Lambert-Eaton myasthenic syndrome (LEMS) — a rare autoimmune disorder so obscure most doctors have never seen a case — giving it a near-monopoly in a tiny but lucrative market.
5
The Lore
The active ingredient in its flagship product, amifampridine, had been used off-label for decades in Europe before this company shepherded it through the rigorous FDA approval process for the U.S. market.
6
The Giveaway
Its FDA-approved drug Firdapse treats LEMS, and the company's name is basically a metaphor for sparking a chemical reaction — fitting for a firm that jumpstarted a forgotten molecule's second life.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving CPRX's Business? Latest 10-Q Breakdown

✓ 33/33 datapoints verified

AI-extracted from CATALYST PHARMACEUTICALS, INC.'s 10-Q filed 2026-05-11 — Q1 FY2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Total revenue rose 5.6% to $149.4M as FIRDAPSE (+18.1%) and AGAMREE (+66.6%) growth offset a 61.3% FYCOMPA collapse, while Catalyst agreed to be acquired by Angelini Pharma for $31.50 per share.

Biggest Revenue Drivers

Product revenue, net$149.3M+5.6% YoY

Primarily driven by increases in sales volumes for both FIRDAPSE and AGAMREE

License and other revenue$47 thousand+123.8% YoY

Consisted of royalties

Biggest Revenue Drivers

Total revenue: $149.4M+5.6% YoY

Product revenue, net$149.3M+5.6% YoY

Primarily driven by increases in sales volumes for both FIRDAPSE and AGAMREE

Within Product revenue, net

FIRDAPSE®$98.9M+18.1% YoY

Increase in sales volumes

AGAMREE®$36.7M+66.6% YoY

Increase in sales volumes

FYCOMPA®$13.8M-61.3% YoY

Generic entry following loss of exclusivity in 2025

License and other revenue$47 thousand+123.8% YoY

Consisted of royalties

Largest Expense Items

Selling, general and administrative$49.3M+5.1% YoY

Increase in general and administrative from consulting fees related to multiple business initiatives, including business development

Cost of sales$14.5M-19% YoY

Primarily a decrease in royalty obligations related to FIRDAPSE

Amortization of intangible assets$9.7M

FYCOMPA, RUZURGI and AGAMREE rights amortized straight-line over 5, 14.5 and 10.5 years

Research and development$2.7M-31.5% YoY

Research and clinical trial expense fell $0.9M, or 45.4%

Margins: Operating income rose to $73.2M from $63.4M as cost of sales fell to $14.5M on lower FIRDAPSE royalties; the overall upstream FIRDAPSE royalty rate dropped to 6% from a prior maximum of 18.5%.

Watch Items from the Filing

Pending merger with Angelini Pharma at $31.50 per share cash; a termination fee of approximately $155.5 million applies under specified circumstances.
Customer A represented 90.1% of total net product revenue, up from 74.0% a year earlier.
FYCOMPA revenue fell to $13.8M from $35.6M; the company expects further declines and ceased all marketing for the product at the end of 2025.
Hetero FIRDAPSE patent litigation settled with market entry no earlier than January 2035, but Catalyst owes an $11.0 million litigation avoidance fee in Q2 2026.
Effective tax rate rose to 24.3% from 20.4%; company also relies on Santhera as sole AGAMREE supplier while transitioning manufacturing by end of 2026.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$149.4M

Net Income

Q1 2026

$63.7M

Free Cash Flow

Q1 2026

$59.6M

Operating Margin

Q1 2026

49.0%

ROIC

Q1 2026

28.9%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+19.8% YoY

$589.0MFY 2025

FY22 $214.2MFY23 $398.2MFY24 $491.7MFY25 $589.0M

Net Income

+30.8% YoY

$214.3MFY 2025

FY22 $83.1MFY23 $71.4MFY24 $163.9MFY25 $214.3M

Operating Income

+32.1% YoY

$257.8MFY 2025

FY22 $101.8MFY23 $86.8MFY24 $195.1MFY25 $257.8M

EPS (Diluted)

+28.2% YoY

$1.68FY 2025

FY22 $0.75FY23 $0.63FY24 $1.31FY25 $1.68

Total Assets

+29.7% YoY

$1.10BFY 2025

FY22 $375.6MFY23 $470.1MFY24 $851.4MFY25 $1.10B

Op. Cash Flow

-13.0% YoY

$208.7MFY 2025

FY22 $116.0MFY23 $143.6MFY24 $239.8MFY25 $208.7M

Free Cash Flow

-12.8% YoY

$208.6MFY 2025

FY22 $116.0MFY23 $143.4MFY24 $239.3MFY25 $208.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$589.0M +19.8%	$491.7M +23.5%	$398.2M +85.9%	$214.2M +52.1%	$140.8M +18.3%	$119.1M
Net Income	$214.3M +30.8%	$163.9M +129.5%	$71.4M -14.0%	$83.1M +110.4%	$39.5M -47.3%	$75.0M
Operating Income	$257.8M +32.1%	$195.1M +124.8%	$86.8M -14.8%	$101.8M +94.4%	$52.4M +26.8%	$41.3M
EPS (Diluted)	$1.68 +28.2%	$1.31 +107.9%	$0.63 -16.0%	$0.75 +102.7%	$0.37 -47.9%	$0.71
Total Assets	$1.10B +29.7%	$851.4M +81.1%	$470.1M +25.2%	$375.6M +58.0%	$237.8M +23.6%	$192.4M
Operating Cash Flow	$208.7M -13.0%	$239.8M +67.0%	$143.6M +23.7%	$116.0M +92.2%	$60.4M +34.1%	$45.0M
Free Cash Flow	$208.6M -12.8%	$239.3M +66.9%	$143.4M +23.6%	$116.0M +95.5%	$59.4M +31.8%	$45.0M

Get alerted when CPRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CATALYST PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CPRX

BlackRock, Inc.
$464.9M18,774,530 sh
STATE STREET CORP
$169.9M6,863,060 sh
VANGUARD CAPITAL MANAGEMENT LLC
$126.8M5,122,666 sh
AMERICAN CENTURY COMPANIES INC
$102.5M4,138,416 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$97.6M3,943,600 sh
DIMENSIONAL FUND ADVISORS LP
$84.9M3,429,615 sh
BANK OF AMERICA CORP /DE/
$75.2M3,036,546 sh
GEODE CAPITAL MANAGEMENT, LLC
$73.6M2,972,402 sh
MORGAN STANLEY
$66.5M2,687,299 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$61.3M2,475,467 sh

Fund	Value	Shares
BlackRock, Inc.	$464.9M	18,774,530
STATE STREET CORP	$169.9M	6,863,060
VANGUARD CAPITAL MANAGEMENT LLC	$126.8M	5,122,666
AMERICAN CENTURY COMPANIES INC	$102.5M	4,138,416
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$97.6M	3,943,600
DIMENSIONAL FUND ADVISORS LP	$84.9M	3,429,615
BANK OF AMERICA CORP /DE/	$75.2M	3,036,546
GEODE CAPITAL MANAGEMENT, LLC	$73.6M	2,972,402
MORGAN STANLEY	$66.5M	2,687,299
VANGUARD PORTFOLIO MANAGEMENT LLC	$61.3M	2,475,467

Companies Similar to CPRX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

INVA

Innoviva, Inc.

AI score

Similar quality profile · 21 shared holders

Boston Partners SYSTEMATIC FINANCIAL MANAGEMENT LP WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC

LGND

LIGAND PHARMACEUTICALS INC

AI score

Similar quality profile · 14 shared holders

KENNEDY CAPITAL MANAGEMENT LLC Moran Wealth Management, LLC NFJ INVESTMENT GROUP, LLC

KRYS

Krystal Biotech, Inc.

AI score

Similar quality profile · 14 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Bridge City Capital, LLC KENNEDY CAPITAL MANAGEMENT LLC

RIGL

RIGEL PHARMACEUTICALS INC

AI score

Similar quality profile · 4 shared holders

LSV ASSET MANAGEMENT Brandywine Global Investment Management, LLC CenterBook Partners LP

ACAD

ACADIA PHARMACEUTICALS INC

AI score

Similar quality profile · 14 shared holders

ROYCE & ASSOCIATES LP CenterBook Partners LP FIRST CITIZENS BANK & TRUST CO

NBIX

NEUROCRINE BIOSCIENCES INC

AI score

Similar quality profile · 10 shared holders

Swedbank AB Boston Partners KENNEDY CAPITAL MANAGEMENT LLC

PEN

Penumbra Inc

AI score

Similar quality profile · 19 shared holders

HBK INVESTMENTS L P GLAZER CAPITAL, LLC WATER ISLAND CAPITAL LLC

VCYT

VERACYTE, INC.

AI score

Similar quality profile · 12 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC OBERWEIS ASSET MANAGEMENT INC/KENNEDY CAPITAL MANAGEMENT LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CPRX on your watchlist

Track score changes the day CATALYST PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CPRX a good stock to buy?

13F Pro's AI-powered analysis of CATALYST PHARMACEUTICALS, INC. (CPRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CPRX are available on the CPRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CPRX is classified as a mid company.

Which hedge funds own CPRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CPRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CATALYST PHARMACEUTICALS, INC.'s investment landscape.